Dialog Box


Idelalisib – (Zydelig®)

Idelalisib is an oral anti-neoplastic medicine that targets B-cell cancers and used in the treatment of double-refractory Follicular Lymphoma (FL) and relapsed Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL).

Idelalisib works by inhibiting PI3K (phosphatidylinositol 3-kinase) which is an enzyme that is overactive in B-cell cancers. By blocking the effects of this enzyme, it affects the growth of malignant lymphocyte cells and causing cell death.

Zydelig® (Idelalisib) is now indicated for the treatment of:

Follicular Lymphoma:

  • Given as a monotherapy for the treatment of refractory FL
  • For patients that are refractory to at least two prior systemic therapies
  • Patients must be refractory to both rituximab and an alkylating agent
  • Recommended for patients over the age of 18 years
Chronic Lymphocytic Leukaemia

  • For patients with relapsed CLL or SLL
  • First line treatment with a 17p deletion or TP53 mutation
  • Given in combination with rituximab for whom chemo-immunotherapy is not considered suitable
  • Recommended for patients over the age of 18 years
 Idelalisib may have the following side effects:

  • Diarrhoea or colitis
  • Hepatotoxicity
  • Rash
  • Pneumonitis
  • Serious infection (eg. CMV or PJP)
  • Fever or severe chills

Further information 

Product information

Fact sheet

Article - "Idelalisib has CLL on the run!"

For further information contact Gilead: http://www.gilead.com/